Please use this identifier to cite or link to this item:
Title: Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
Authors: Fujioka, K.
O'Neil, P. M.
Davies, Melanie
Greenway, F.
Lau, D. C. W.
Claudius, B.
Vang Skjøth, T.
Bjørn Jensen, C.
Wilding, J. P. H.
First Published: 2-Nov-2016
Publisher: Wiley for Obesity Society
Citation: Obesity (2016) 24, 2278–2288
Abstract: OBJECTIVE: To identify an early response criterion for predicting ≥5% weight loss with liraglutide 3.0 mg at week 56 and to compare efficacy outcomes in early responders (ERs) and early nonresponders (ENRs). METHODS: Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks. Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment. RESULTS: Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D). Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D). In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg. Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs. CONCLUSIONS: The early response criterion was clinically useful to identify individuals who would achieve clinically meaningful weight loss at 56 weeks.
DOI Link: 10.1002/oby.21629
ISSN: 1930-7381
eISSN: 1930-739X
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: © 2016 The Authors Obesity published by Wiley Periodicals, Inc. on behalf of The Obesity Society (TOS) This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Appears in Collections:Published Articles, Dept. of Cardiovascular Sciences

Files in This Item:
File Description SizeFormat 
s1-ln24122199-441834075-1939656818Hwf-1880699259IdV208402510724122199PDF_HI0001-1.pdfPublished (publisher PDF)1.11 MBAdobe PDFView/Open

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.